Show simple item record

dc.creatorBužančić, Iva
dc.creatorDržaić, Margita
dc.creatorKummer, Ingrid
dc.creatorOrtner Hadžiabdić, Maja
dc.creatorBrkić, Jovana
dc.creatorFialová, Daniela
dc.date.accessioned2024-03-26T14:45:57Z
dc.date.available2024-03-26T14:45:57Z
dc.date.issued2024
dc.identifier.issn2045-2322
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5571
dc.description.abstractPharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.
dc.publisherNature Research
dc.relationThe EuroAgeism H2020 project (ESR7 project)
dc.relationThe European Union research and innovation program
dc.relationThe Grant Agreement of the Marie Skłodowska-Curie Founda- tion Number MSCF-ITN-764632
dc.relationThe Grants: InoMed, Reg. No CZ.02.1.01/0.0/0.0/18_069/0010046
dc.relationThe European Horizon 2020 I-CARE4OLD Grant No 965341
dc.relationSTART/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935
dc.relationSVV 260 551 Grant
dc.relationCooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Therapeutic Value of Drugs in the Aged’’, KSKF-I.
dc.relationNETPHARM project CZ.02.01.01/00/22_008/0004607
dc.relation.isreferencedbyhttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5621
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScientific Reports
dc.subjectGeriatrics
dc.subjectDeprescribing
dc.subjectGeriatric assessment
dc.subjectHealthy ageing
dc.subjectPolypharmacy
dc.titleDeprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment
dc.typearticle
dc.rights.licenseBY
dc.citation.volume14
dc.citation.issue1
dc.citation.spage6235
dc.description.otherhttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5621
dc.identifier.wos001185787000054
dc.identifier.doi10.1038/s41598-024-56780-1
dc.identifier.pmid38485992
dc.identifier.scopus2-s2.0-85187891254
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/15725/Deprescribing_potential_of_pub_2024.pdf
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record